{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:50:41Z","timestamp":1787878241219,"version":"build-2784847793"},"reference-count":29,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","ashjournal.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Society of Hypertension"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.jash.2018.08.001","type":"journal-article","created":{"date-parts":[[2018,8,10]],"date-time":"2018-08-10T12:40:11Z","timestamp":1533904811000},"page":"768-778.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Cardiovascular safety of mirabegron: analysis of an integrated clinical trial database of patients with overactive bladder syndrome"],"prefix":"10.1016","volume":"12","author":[{"given":"William B.","family":"White","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emad","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tri","family":"Tat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Billy","family":"Franks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol R.","family":"Schermer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jash.2018.08.001_bib1","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.juro.2015.01.087","article-title":"Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline amendment","volume":"193","author":"Gormley","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.jash.2018.08.001_bib2","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/nrurol.2017.113","article-title":"Pharmacology: cardiovascular effects of mirabegron","volume":"14","author":"Andersson","year":"2017","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.jash.2018.08.001_bib3","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1517\/14740338.2013.813016","article-title":"Cardiovascular effects of antimuscarinic agents in overactive bladder","volume":"12","author":"Rosa","year":"2013","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jash.2018.08.001_bib4","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1365-2125.2010.03813.x","article-title":"Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction","volume":"72","author":"Andersson","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jash.2018.08.001_bib5","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/17512433.2017.1275570","article-title":"Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia","volume":"10","author":"Chapple","year":"2017","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.jash.2018.08.001_bib6","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1111\/bph.13897","article-title":"The beta3 -adrenoceptor agonist mirabegron increases human atrial force through beta1 -adrenoceptors: an indirect mechanism?","volume":"174","author":"Mo","year":"2017","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jash.2018.08.001_bib7","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1002\/jcph.952","article-title":"An exploratory study in healthy male subjects of the mechanism of mirabegron-induced cardiovascular effects","volume":"57","author":"van Gelderen","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jash.2018.08.001_bib8","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.vascn.2017.04.008","article-title":"Translational science approach for assessment of cardiovascular effects and proarrhythmogenic potential of the beta-3 adrenergic agonist mirabegron","volume":"87","author":"Korstanje","year":"2017","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1016\/j.jash.2018.08.001_bib10","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1464-410X.2009.09073.x","article-title":"Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder","volume":"106","author":"Andersson","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.jash.2018.08.001_bib11","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.eururo.2014.02.012","article-title":"Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony)","volume":"67","author":"Abrams","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.jash.2018.08.001_bib12","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1177\/1756287215589250","article-title":"The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial","volume":"7","author":"Batista","year":"2015","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.jash.2018.08.001_bib13","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s00192-013-2042-x","article-title":"A phase II dose-ranging study of mirabegron in patients with overactive bladder","volume":"24","author":"Chapple","year":"2013","journal-title":"Int Urogynecol J"},{"key":"10.1016\/j.jash.2018.08.001_bib14","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.eururo.2012.10.048","article-title":"Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta(3)-adrenoceptor agonist, in overactive bladder","volume":"63","author":"Chapple","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.jash.2018.08.001_bib15","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.urology.2013.02.077","article-title":"A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the beta(3) adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder","volume":"82","author":"Herschorn","year":"2013","journal-title":"Urology"},{"key":"10.1016\/j.jash.2018.08.001_bib16","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/bju.13882","article-title":"Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study)","volume":"120","author":"Herschorn","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.jash.2018.08.001_bib17","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.eururo.2012.10.016","article-title":"Efficacy and tolerability of mirabegron, a beta(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial","volume":"63","author":"Khullar","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.jash.2018.08.001_bib18","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/nau.22645","article-title":"Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a beta3-adrenoceptor agonist, in patients with overactive bladder in Asia","volume":"34","author":"Kuo","year":"2015","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.jash.2018.08.001_bib19","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.juro.2012.10.017","article-title":"Results of a randomized phase III trial of mirabegron in patients with overactive bladder","volume":"189","author":"Nitti","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.jash.2018.08.001_bib20","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.juro.2013.05.062","article-title":"Urodynamics and safety of the beta(3)-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction","volume":"190","author":"Nitti","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.jash.2018.08.001_bib21","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00192-017-3377-5","article-title":"A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study)","volume":"29","author":"Staskin","year":"2018","journal-title":"Int Urogynecol J"},{"key":"10.1016\/j.jash.2018.08.001_bib22","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/luts.12053","article-title":"Efficacy and safety of the selective beta3-adrenoceptor agonist mirabegron in Japanese patients with overactive bladder: a randomized, double-blind, placebo-controlled, dose-finding study","volume":"7","author":"Yamaguchi","year":"2015","journal-title":"Low Urin Tract Symptoms"},{"key":"10.1016\/j.jash.2018.08.001_bib23","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/bju.12649","article-title":"Phase III, randomised, double-blind, placebo-controlled study of the beta3-adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder","volume":"113","author":"Yamaguchi","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.jash.2018.08.001_bib24","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/luts.12107","article-title":"Phase III study to assess long-term (52-week) safety and efficacy of mirabegron, a beta3-adrenoceptor agonist, in Japanese patients with overactive bladder","volume":"9","author":"Yamaguchi","year":"2017","journal-title":"Low Urin Tract Symptoms"},{"key":"10.1016\/j.jash.2018.08.001_bib26","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","article-title":"The use of confidence or fiducial limits illustrated in the case of the binomial","volume":"26","author":"Clopper","year":"1934","journal-title":"Biometrika"},{"key":"10.1016\/j.jash.2018.08.001_bib27","series-title":"Statistical power analysis for the behavioral sciences","author":"Cohen","year":"1988"},{"key":"10.1016\/j.jash.2018.08.001_bib28","author":"Leonard"},{"key":"10.1016\/j.jash.2018.08.001_bib29","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s40801-017-0124-7","article-title":"Replication of Mini-Sentinel study assessing mirabegron and cardiovascular risk in non-Mini-Sentinel databases","volume":"5","author":"Simeone","year":"2018","journal-title":"Drugs Real World Outcomes"},{"key":"10.1016\/j.jash.2018.08.001_bib30","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/luts.12148","article-title":"Safety and effectiveness of mirabegron in patients with overactive bladder in a real-world clinical setting: a Japanese post-marketing study","volume":"10","author":"Nozawa","year":"2018","journal-title":"Low Urin Tract Symptoms"},{"key":"10.1016\/j.jash.2018.08.001_bib31","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ejogrb.2016.05.048","article-title":"Safety and efficacy of mirabegron in daily clinical practice: a prospective observational study","volume":"203","author":"Kallner","year":"2016","journal-title":"Eur J Obstet Gynecol Reprod Biol"}],"container-title":["Journal of the American Society of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933171118302419?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933171118302419?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,23]],"date-time":"2018-12-23T11:07:41Z","timestamp":1545563261000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933171118302419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S1933171118302419"],"URL":"https:\/\/doi.org\/10.1016\/j.jash.2018.08.001","relation":{},"ISSN":["1933-1711"],"issn-type":[{"value":"1933-1711","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular safety of mirabegron: analysis of an integrated clinical trial database of patients with overactive bladder syndrome","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Society of Hypertension","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jash.2018.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 American Heart Association. All rights reserved.","name":"copyright","label":"Copyright"}]}}